A Multicenter Retrospective Analysis of Survival Outcome Following Postoperative Chemoradiotherapy in Non-Small-Cell Lung Cancer Patients With N2 Nodal Disease

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 2, 2010, Pages 321-328

  Zou, Bingwen ^a   Xu, Yong ^a   Li, Tao ^b   Li, Wenhui ^c   Tang, Bangxian ^d   Zhou, Lin ^a   Li, Lu ^a   Liu, Yongmei ^a   Zhu, Jiang ^a   Huang, Meijuan ^a   Wang, Jin ^a   Ren, Li ^a   Gong, Youlin ^a   Che, Guowei ^a   Liu, Lunxu ^a   Hou, Mei ^a   Lu, You ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN CANCER HOSPITAL   (China)

^c Department of Medical Oncology   (China)

^d AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

N2; NSCLC; Operation; Postoperative chemoradiotherapy; Radiotherapy

Indexed keywords

ADJUVANT TREATMENT; CHEMORADIOTHERAPY; CLINICAL TARGET VOLUMES; DISEASE FREE SURVIVAL; LYMPH NODE; MEDIAN RADIATION; MULTI VARIATE ANALYSIS; N2; NODAL STATUS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL RATES; PLATINUM-BASED CHEMOTHERAPY; PROGNOSTIC FACTORS; RETROSPECTIVE ANALYSIS; SOUTHWEST CHINA; TREATMENT MODALITY;

BIOLOGICAL ORGANS; CHEMOTHERAPY; DECISION MAKING; DOSIMETRY; MULTIVARIANT ANALYSIS; PLATINUM;

RADIOTHERAPY;

CISPLATIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CHINA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SURVIVAL RATE; TREATMENT FAILURE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PACLITAXEL; POSTOPERATIVE CARE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77951963496     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.05.044     Document Type: Article

References (29)

1. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., et al. Clinical prognostic factors in surgically treated stage IIIAN2 non small cell lung cancer: Analysis of the literature. Lung Cancer 19 (1998) 3-13
2. Betticher D.C., Schmitz S.F.H., Totsch M., et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: The 5-year follow-up of a phase II study. Br J Cancer 94 (2006) 1099-1106
3. International Adjuvant Lung cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350 (2004) 351-360
4. Winton T.L., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs observation in resected non-small cell lung cancer Intergroup. N Engl J Med 352 (2005) 2589-2597
5. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised trial. Lancet Oncol 7 (2006) 719-727
6. PORT Meta-analysis Trialists Group: Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet 352 (1998) 257-263
7. Burdett S., and Stewart L. Postoperative radiotherapy in non-small cell lung cancer: Update of an individual patient data meta analysis. Lung Cancer 47 (2005) 81-83
8. Lally B.E., Zelterman D., Colasanto J.M., et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the Surveillance, Epidemiology, and End Results Database. J Clin Oncol 24 (2006) 2998-3006
9. Sawyer T.E., Bonner J.A., Gould P.M., et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg 64 (1997) 1402-1407
10. Debevec M., Bitenc M., Vidmar S., et al. Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NSCLC): Randomized clinical study 1988-1992. Lung Cancer 14 (1996) 99-107
11. Feng Q.F., Wang M., Wang L.J., et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: A randomized trial. Int J Radiat Oncol Biol Phys 47 (2000) 925-929
12. Hsu H.-C., Wang C.-J., Huang E.-Y., et al. Post-operative adjuvant thoracic radiotherapy for patients with completely resected non-small cell lung cancer with nodal involvement: Outcome and prognostic factors. Br J Radiol 77 (2004) 43-48
13. Misthos P., Sepsas E., Athanassiadi K., et al. Skip metastases: Analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer. Eur J Cardiothorac Surg 25 (2004) 502-508
14. Riquet M., Assouad J., Bagan P., et al. Skip mediastinal lymph node metastasis and lung cancer: A particular N2 subgroup with a better prognosis. Ann Thorac Surg 79 (2005) 225-233
15. Le Péchoux C., De Ruysscher D., Francoise Mornex F., et al. Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 Mediastinal Involvement. J Clin Oncol 7 (2007) e10-e11
16. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
17. Lawless J.F. Statistical models and methods for lifetime data (1982), Wiley, New York
18. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1711-1717
19. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
20. Logan D.M., Lochrin C.A., Darling G., et al. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small cell lung cancer after complete resection. Cancer Prev Control 1 (1997) 366-378
21. Okawara G., Ung Y.C., Markman B.R., et al. Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: A systematic review and practice guideline. Lung Cancer (Amsterdam, Netherlands) 44 (2004) 1-11
22. Wang X.S., Lu C., Shi Q., et al. Symptom burden and survival outcome: 3 cycles versus 6 cycles of chemotherapy in advanced NSCLC. ASCO Mtg Abstr (Jun 2007) (abstr 25: 17054)
23. Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 315 (1986) 1377-1381
24. Mayer R., Smolle-Juettner F.M., Szolar D., et al. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest 112 (1997) 954-959
25. Sawyer T.E., Bonner J.A., Gould P.M., et al. The impact of surgical adjuvant thoracic radiation therapy for patients with non-small cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer 80 (1997) 1399-1408
26. Douillard J.-Y., Rosell R., De Lena M., et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys 72 (2008) 695-701
27. Stephens R.J., Girling D.J., Bleehen N.M., et al. The role of post-operative radiotherapy in non-small-cell lung cancer: A multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Br J Cancer 74 (1996) 632-639
28. Machtay M., Lee J.H., Shrager J.B., et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol 19 (2001) 3912-3917
29. Tanaka F., Yanagihara K., Ohtake Y., et al. Time trends and survival after surgery for p-stage IIIa, pN2 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 12 (1997) 372-379